Doxorubicin chemotherapy for presumptive cardiac hemangiosarcoma in dogs

Doxorubicin chemotherapy for presumptive cardiac hemangiosarcoma in dogs

Sixty‐four dogs were treated with single‐agent doxorubicin (DOX) for presumptive cardiac hemangiosarcoma (cHSA). The objective response rate (CR + PR) was 41%, and the biologic response rate (CR + PR + SD), or clinical benefit, was 68%. The median progression‐free survival (PFS) for treated dogs was...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Veterinary & comparative oncology 2016-12, Vol.14 (4), p.e171-e183
Hauptverfasser: Mullin, C.M., Arkans, M.A., Sammarco, C.D., Vail, D.M., Britton, B.M., Vickery, K.R., Risbon, R.E., Lachowicz, J., Burgess, K.E., Manley, C.A., Clifford, C.A.
Format: Artikel
Sprache:eng
Schlagworte:
Animals
Antibiotics, Antineoplastic - therapeutic use
Case-Control Studies
chemotherapy
Dog Diseases - drug therapy
Dogs
Doxorubicin - therapeutic use
Female
Heart Neoplasms - drug therapy
Heart Neoplasms - veterinary
Hemangiosarcoma - drug therapy
Hemangiosarcoma - veterinary
Male
metastasis
oncology
Retrospective Studies
small animal
surgical oncology
Survival Analysis
tumour biology
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Sixty‐four dogs were treated with single‐agent doxorubicin (DOX) for presumptive cardiac hemangiosarcoma (cHSA). The objective response rate (CR + PR) was 41%, and the biologic response rate (CR + PR + SD), or clinical benefit, was 68%. The median progression‐free survival (PFS) for treated dogs was 66 days. The median survival time (MST) for this group was 116 days and was significantly improved compared to a MST of 12 days for untreated control dogs (P = 0.0001). Biologic response was significantly associated with improved PFS (P 
ISSN:1476-5810
1476-5829
DOI:10.1111/vco.12131